AI주식인사이트AI Stock Insight
D

이엔셀

456070KOSDAQ

38.0 / 100

Reference Date: 2026-10-23

Financial Score11.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 4.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

InCell operates two business models based on its GMP technology for cell and gene therapy drug development: CDMO (Contract Development and Manufacturing Organization) for advanced biopharmaceuticals and the development of next-generation cell and gene therapy drugs. The company holds the only GMP facility in South Korea capable of simultaneous cell and virus production, focusing on therapies for rare diseases like Charcot-Marie-Tooth and Duchenne muscular dystrophy.

Number of Employees

112people

Average Salary

42.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.38Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-36.79Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
53.53Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2024~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼27.1% (1-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼14.2% (1-year basis)

ROE Trend
0.0 / 4

Avg ROE -36.0% (declining, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,940Won52-week high 20,15052-week low 4,835
1-month return2.0Point

1m -4.26% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0